NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Genpact (NYSE: G), a global professional services firm focused on delivering outcomes that transform businesses, announced a new multi-year agreement with GE HealthCare (NYSE: GEHC) to transform and manage its US leasing and lending operations.
The collaboration will leverage Genpact's digital technology solutions, specifically its business-process-as-a-service (BPaaS) operating model, to strengthen GE HealthCare's capabilities for customers acquiring new medical equipment through its existing suite of equipment loan and lease products. The BPaaS operating model is integrated with Genpact's AI-powered platform, Genpact Cora, offering a scalable and agile solution to help meet the company's needs.
This innovative solution has an open architecture, integrating generative AI and other emerging digital technologies. Adopting this platform gives GE HealthCare access to essential business benchmarks and insights, and key performance indicators, with upgrades and enhancements available to meet evolving market and customer demands flexibly.
"Rapid innovation in the healthcare industry compels leaders like GE HealthCare to continuously evolve their operating models, driving efficiencies and value beyond financial outcomes," said Anil Nanduru, Global Business Leader, High Tech and Manufacturing, Genpact. "We take pride in our longstanding history of co-innovation with GE HealthCare. We look forward to unlocking further meaningful value for both the organization and its customers, empowering them to thrive in a rapidly changing environment."
GE HealthCare's US-based customers will benefit from Genpact's deep domain in healthcare and life sciences, and its expertise in the leasing and financial services industries, providing them with access to valuable insights and specialized knowledge in equipment finance, portfolio management, and customer operations support.
About Genpact
Genpact (NYSE: G) is a global professional services firm delivering the outcomes that transform our clients' businesses and shape their future. We're guided by our real-world experience redesigning and running thousands of processes for hundreds of global companies. Our clients – including many in the Global Fortune 500 – partner with us for our unique ability to combine deep industry and functional expertise, leading talent, and proven methodologies to drive collaborative innovation that turns insights into action and delivers outcomes at scale. We create lasting competitive advantages for our clients and their customers, running digitally enabled operations and applying our Data-Tech-AI services to design, build, and transform their businesses. And we do it all with purpose. From New York to New Delhi and more than 30 countries in between, our 115,000+ team is passionate in its relentless pursuit of a world that works better for people. Get to know us at Genpact.com and on LinkedIn, Twitter, YouTube, and Facebook.
MEDIA CONTACTS:
Siya Belliappa
Genpact Media Relations
+1 7185619843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$81.76 |
Daily Change: | -1.16 -1.40 |
Daily Volume: | 3,609,013 |
Market Cap: | US$37.340B |
November 12, 2024 October 30, 2024 October 21, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB